{"nctId":"NCT00640614","briefTitle":"Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy","startDateStruct":{"date":"2008-04"},"conditions":["Contact Dermatitis"],"count":235,"armGroups":[{"label":"Sensitives","type":"EXPERIMENTAL","interventionNames":["Biological: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens"]},{"label":"Consecutives","type":"EXPERIMENTAL","interventionNames":["Biological: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens"]}],"interventions":[{"name":"T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens","otherNames":["T.R.U.E. TEST® Skin Patch Test: Panel 3.2"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Consecutive subjects must report symptoms and/or history consistent with allergic contact dermatitis to at least one of the allergens tested in the study (i.e., subjects are visiting the clinic/physician to diagnose, treat or resolve this condition).\n* Sensitive subjects must have a positive patch test to one of the following allergens within the past 10 years.\n\n  * Gold sodium thiosulfate\n  * Methyldibromoglutaronitrile (alone or with phenoxyethanol)\n  * Bacitracin\n  * Bronopol\n  * Disperse blue 106 (alone or with Disperse blue 124)\n  * Parthenolide (or Compositae mix)\n  * Hydrocortisone-17-butyrate\n* All subjects must be adults over 18 years of age, and otherwise in good health.\n* Premenopausal female subjects with childbearing potential must consent to a urine pregnancy test; urine test results must be negative for study inclusion.\n* Informed consent must be signed and understood by each subject, and consistent with all institutional, local and national regulations.\n\nExclusion Criteria:\n\n* Subjects unable to meet inclusion requirements.\n* Women who are breastfeeding or pregnant.\n* Topical corticosteroid treatment during the last 7 days before visit 1 on or near the test area.\n* Systemic treatment with corticosteroids or other immunosuppressants during the last 7 days.before visit 1.\n* Subjects currently receiving (or received in the 21 days before visit 1) other investigational drugs, treatments or devices, or participating in another clinical study.\n* Treatment with ultraviolet (UV) light (including tanning) during the 21 days before visit\n* Acute dermatitis outbreak or dermatitis on or near the test area on the back.\n* Subjects unable to comply with patch test study requirements including multiple return visits and activity restrictions (e.g., protecting test panels from excess moisture due to showering or vigorous activity).","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Diagnostic Performance: Concordance Between Investigational Allergen and Reference Allergen at Day 21","description":"Concordance: Percentage of subjects who responded positively to T.R.U.E. Test allergen gold sodium thiosulfate and the reference allergen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Diagnostic Performance: Concordance","description":"Concordance: Percentage of subjects who responded positively to T.R.U.E. Test allergen hydrocortisone-17-butyrate and the reference allergen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null}]}]}]},{"type":"PRIMARY","title":"Diagnostic Performance: Concordance","description":"Concordance: Percentage of subjects who responded positively to T.R.U.E. Test allergen methyldibromo-glutaronitrile and the reference allergen.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Diagnostic Performance: Concordance","description":"Concordance: Percentage of subjects who responded positively to TRUE Test allergen bacitracin and the reference allergen.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null}]}]}]},{"type":"PRIMARY","title":"Diagnostic Performance: Concordance","description":"Concordance: Percentage of subjects who responded positively to TRUE Test allergen parthenolide and the reference allergen.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Diagnostic Performance: Concordance","description":"Concordance: Percentage of subjects who responded positively to T.R.U.E. Test allergen disperse blue and the reference allergen.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Diagnostic Performance: Concordance","description":"Concordance: Percentage of subjects who responded positively to T.R.U.E. Test allergen bronopol and the reference allergen.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Diagnostic Performance: Sensitivity and Specificity: Gold Sodium Thiosulfate","description":"Percentage of subjects with positive (sensitivity) and negative (specificity) results to the investigational allergen and the reference allergen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"57.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Diagnostic Performance: Sensitivity and Specificity: Hydrocortisone-17-butyrate","description":"The percentage of subjects with positive (sensitivity) and negative (specificity) results to the investigational allergen and the reference allergen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null},{"groupId":"OG001","value":"85.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Diagnostic Performance: Sensitivity and Specificity: Methyldibromo-glutaronitrile","description":"The percentage of subjects with positive (sensitivity) and negative (specificity) results to the investigational allergen and the reference allergen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":null},{"groupId":"OG001","value":"93.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Diagnostic Performance: Sensitivity and Specificity: Bacitracin","description":"The percentage of subjects with positive (sensitivity) and negative (specificity) results to the investigational allergen and the reference allergen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]}]},{"type":"PRIMARY","title":"Diagnostic Performance: Sensitivity and Specificity: Parthenolide","description":"The percentage of subjects with positive (sensitivity) and negative (specificity) results to the investigational allergen and the reference allergen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Diagnostic Performance: Sensitivity and Specificity: Disperse Blue","description":"The percentage of subjects with positive (sensitivity) and negative (specificity) results to the investigational allergen and the reference allergen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Diagnostic Performance: Sensitivity and Specificity: Bronopol","description":"The percentage of subjects with positive (sensitivity) and negative (specificity) results to the investigational allergen and the reference allergen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"78.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Evaluations: All T.R.U.E. Test Allergens","description":"Safety Evaluations: Number of participants who experienced Tape Irritation, Itching or Burning and measure of how well patches adhered to the skin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"123","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Late Reactions: All T.R.U.E. Test Allergens","description":"Number of subjects who exhibited Late Reactions (reactions that occur at 7-10 days after application).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Persistent Reactions: All T.R.U.E. Test Allergens","description":"Number of Subjects who exhibited Persistent Reactions (reactions that initially occur at 2-4 days after application and persist through 7-21 days after application)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"12","spread":null},{"groupId":"OG005","value":"5","spread":null},{"groupId":"OG006","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":125},"commonTop":["Pruritus","Bruise on mid sternum from motor vehicle accident","Upper respiratory congestion","Common head cold symptoms","Asthma"]}}}